Easy, Accurate and Affordable Cancer Screening....Welcome to the Beacon Revolution!

The Technologies We Choose Are The Ones That You'll Use

At Beacon Biomedical we develop highly accurate, easy to administer and extremely affordable point-of-care tests for the early detection of cancers.  This is our business and we do it because we are passionate about saving lives. 


It has often been said that the best test or products in the market can be easily recognized because ....they are the ones being used.   So, our business model is a simple one.  We do not invent or create new molecular tumor-associated biomarkers or medical devices for cancer screening.  Rather, we are innovators and experts at finding, securing and then leveraging already existing technologies that can be employed synergistically for earlier cancer detection and screening  purposes.


This approach allows Beacon to rapidly evaluate promising new and existing technologies and advance them to the market in shorter periods of time  where they can do the most good as point-of-care tests for initial cancer screening.  This approach also allows us to keep our costs down and provide tests that our in line with what people can afford.  And in taking this approach, we can create highly accurate point-of-care tests for cancer screening and detection that will be readily adopted and used. 


Our Technologies

Beacon Biomedical has two patented technologies for  the development and commercialization of its point-of-care cancer screening and detection tests.  


Signaling Protein.  The foundational protein for Beacon's point-of-care tests is called teratocarcinoma derived growth factor-1, aka Cripto-1, and was licensed from the National Institutes of Health and National Cancer Institute for exclusive use by Beacon in developing and commercializing point-of-care tests and test kits for early cancer recognition, detection, screening and monitoring purposes. Cripto-1 is a required protein for tumor formation, progression and invasion, and has been detected in 50-100% of carcinomas of the breast, colon, lung, pancreas, gallbladder, stomach, endometrium and cervix.


Point-of-Care Device.  Beacon's  is presently evaluating multiple point-of-care (POC) test platforms for its cancer screening tests.  Each of these platforms use patented technologies from manufactures who are leaders in rapid point-of-care testing, have received FDA and CE Mark approvals for their respective product lines, and can serve as Beacon's OEM manufacturing contractors having ISO & GMP compliant manufacturing facilities with world-wide coverage providing both scalability as well as potential global sales/distribution channels for Beacon's cancer screening POC tests. Beacon's POC blood-based tests are being designed for doctors to be able to screen their patients for the presence of undiagnosed cancers, in their offices, in under 10-minutes.  Easy, accurate and affordable cancer screening in real-time from a simple finger-prick of blood.


Our Technologies